ABL1 and acute lymphoblastic leukemia: As an example, Tanasi et al., 2019, reported an experience in a small cohort of Ph-like ALL patients positive to Abl-class fusions in which the introduction of TKIs during consolidation improved the post-induction minimal residual disease (PI-MRD) negative status with values below 10−4, compared with the PI-MRD ≥ 10−2 value observed in patients without TKIs-added chemotherapy.